Your browser doesn't support javascript.
loading
تبين: 20 | 50 | 100
النتائج 1 - 16 de 16
المحددات
إضافة المرشحات








النطاق السنوي
1.
Clin. biomed. res ; 40(2)2020. ilus
مقالة ي الانجليزية | LILACS | ID: biblio-1148189

الملخص

Introduction: Human immunodeficiency virus (HIV), which causes Acquired Immunodeficiency Syndrome, still affects millions of people worldwide. Despite recent advances in the understanding of biological mechanisms of viral replication, there are relevant gaps regarding the virus-host relationship. Unraveling these complexities may lead to the development of new therapeutic strategies and the establishment of new biomarkers useful for the diagnosis and prognosis of infection and its comorbidities. Therefore, in this study we discuss the main biological characteristics of microRNAs and the potential use of these nucleic acids in their free circulating form as indicators of risk or protection against HIV infection. Methods: A narrative review of the literature was carried out in the following databases through keyword and/or health descriptor searches: i) Google Scholar; ii) CAPES periodicals portal; iii) United States National Library of Medicine (PubMed) and iv) Elsevier's Science Direct library. The keywords "microRNA; HIV infection; circulating microRNA; biomarkers" were used to search the databases as mentioned above.Results: Circulating microRNAs (ci-miRNA) are closely related to numerous processes in the HIV infection pathophysiology. They are involved in viral latency, increased viremia, hepatic injury, heart dysfunction, pulmonary hypertension, immune response impairment, and participate in Kaposi's sarcoma pathology. Additionally, these molecules may indicate protection in elite controllers, reduce viral replication and load, and be useful markers of the infection's eclipse phase. Conclusion: Ci-miRNA levels are altered levels in individuals with HIV, playing a dual role in infection. Advances in research have shown that ci-miRNAs could differentiate stages of HIV infection and diseases associated with a viral infection and serve as biomarkers for antiretroviral therapy's effectiveness through changes in their expression. (AU)


الموضوعات
Humans , HIV Infections/diagnosis , MicroRNAs , Virus Replication/immunology , Biomarkers
2.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;51(1): 66-70, Jan.-Feb. 2018. graf
مقالة ي الانجليزية | LILACS | ID: biblio-1041442

الملخص

Abstract INTRODUCTION: Pseudo-infectious yellow fever viral particles (YFV-PIVs) have been used to study vaccines and viral packaging. Here, we report the development of a packaging cell line, which expresses the YFV prM/E proteins. METHODS: HEK293 cells were transfected with YFV prM/E and C (84 nt) genes to generate HEK293-YFV-PrM/E-opt. The cells were evaluated for their ability to express the heterologous proteins and to package the replicon repYFV-17D-LucIRES, generating YFV-PIVs. RESULTS: The expression of prM/E proteins was confirmed, and the cell line trans-packaged the replicon for recovery of a reporter for the YFV-PIVs. CONCLUSIONS: HEK293-YFV-prM/E-opt trans-packaging capacity demonstrates its possible biotechnology application.


الموضوعات
Humans , Virus Replication/immunology , Yellow fever virus/immunology , Virus Assembly/immunology , Vaccines, Virus-Like Particle/immunology , Virus Replication/genetics , Yellow fever virus/genetics , Virus Assembly/genetics , Fluorescent Antibody Technique, Indirect , Green Fluorescent Proteins , HEK293 Cells , Vaccines, Virus-Like Particle/genetics , Flow Cytometry
3.
Rev. chil. infectol ; Rev. chil. infectol;34(3): 249-256, jun. 2017. ilus, tab
مقالة ي الأسبانية | LILACS | ID: biblio-899708

الملخص

Dengue fever, caused by dengue virus (DENV) infection, is one of the most important diseases in the world, not only due to the high morbidity/mortality rates it causes, but also because of its great economic and social impact in tropical/subtropical countries. DENV infection has a wide range of clinical manifestations ranging from asymptomatic infection or infection with mild symptoms to severe dengue that can lead to death. At present, no etiological treatment or effective globally distributed vaccine against the four DENV serotypes exists. Despite great efforts made to understand the mechanism associated with DENV disease pathogenesis the causes leading to severe dengue presentation have not been clarified. Some hypotheses seek to give a biological and physiological explanation to the clinical manifestations that appear during the infection. Based on the evidence that after contact with dendritic cells DENV alters the functionality of these cells, this review aims to describe the most relevant findings regarding the importance of dendritic cells in the context of DENV infection and progression of the illness.


El dengue, causada por el virus dengue (DENV), es una de las enfermedades más importantes no sólo por los altos índices de morbilidad/mortalidad, sino también por su gran impacto económico y social en los países de las regiones tropicales/subtropicales. La infección por el DENV cursa por un variado rango de manifestaciones clínicas que van desde una infección asintomática o con síntomas leves, hasta el dengue grave que puede ser fatal. En la actualidad, no se dispone de un tratamiento etiológico y tampoco de una vacuna eficaz mundialmente distribuida, contra los 4 serotipos del DENV. A pesar de los grandes esfuerzos orientados a entender el mecanismo asociado con la patogénesis de la enfermedad, aún no se ha logrado esclarecer de forma definitiva las causas que conllevan a las formas graves de enfermedad. Algunas hipótesis buscan dar una explicación biológica y fisiológica a las manifestaciones clínicas que se presentan durante la infección. Dado que una de ellas sugiere que luego del contacto con las células dendríticas el DENV altera su funcionalidad, la presente revisión tiene como objetivo describir los hallazgos más relevantes referentes a la importancia de dichas células en el marco de la infección por el DENV y progresión de la enfermedad.


الموضوعات
Humans , Virus Replication/immunology , Dendritic Cells/immunology , Dengue/immunology , Dengue Virus/immunology , Disease Progression , Immunity, Cellular , Immunity, Innate
4.
An. acad. bras. ciênc ; 89(1,supl): 675-684, May. 2017. tab, graf
مقالة ي الانجليزية | LILACS | ID: biblio-886657

الملخص

ABSTRACT The BK virus (BKV) produces a subclinical kidney infection in immunocompetent individuals. However, viremia may occur in kidney transplant patients with ongoing immunosuppression. BKV-associated nephropathy (BKVN) has no specific treatment and is a leading cause of organ transplant loss. In this study, we evaluated the predisposition and the clinical impact of BKV replication in kidney transplant patients during post-transplant monitoring in a reference institution in Brazil. Demographic, clinical and laboratory data generated during routine outpatient follow-up were retrospectively collected. BK viremia was investigated using real-time polymerase chain reaction. Of the 553 participants, 7.4% (n = 41) presented BKV replication. Of these, 16 (39%) lost their kidney graft and interstitial nephritis was identified on kidney biopsy in 50% of the cases. Among the evaluated variables, only the use of the immunosuppressant mycophenolate sodium was identified as a risk factor for viremia (OR 7.96; 95% CI 2.35 to 26.98). The graft survival estimate in BKV-positive patients was significantly reduced (24.8% vs. 85.6%) after 10 years of transplantation. We concluded that defining predisposing factors remains an important challenge for the prevention and control of BKV activity following kidney transplantation, especially considering the development of BKVN and its strong effect on graft maintenance.


الموضوعات
Humans , Male , Female , Adult , Tumor Virus Infections/complications , Viremia/complications , Virus Replication/immunology , Kidney Transplantation/adverse effects , BK Virus/physiology , Polyomavirus Infections/complications , Tumor Virus Infections/virology , Viremia/virology , Cross-Sectional Studies , Retrospective Studies , Risk Factors , Polyomavirus Infections/virology , Graft Rejection
5.
Biomédica (Bogotá) ; Biomédica (Bogotá);37(1): 131-140, ene.-feb. 2017. graf
مقالة ي الأسبانية | LILACS | ID: biblio-888451

الملخص

Resumen Introducción: El dengue es una enfermedad causada por uno de los cuatro serotipos del virus del dengue (DENV) y es endémica en, aproximadamente, 130 países. Su incidencia ha aumentado notablemente en las últimas décadas, así como la frecuencia y la magnitud de los brotes. A pesar de los esfuerzos, no existen tratamientos profilácticos ni terapéuticos contra la enfermedad y, en ese contexto, el estudio de los procesos que gobiernan el ciclo de infección del DENV es esencial para desarrollar vacunas o terapias antivirales. Una de las moléculas del DENV más prometedoras es la proteína no estructural 3 (NS3), la cual es indispensable para la replicación viral y es uno de los principales blancos inmunológicos durante la infección. Objetivo: Producir anticuerpos policlonales para contribuir a los futuros estudios sobre las interacciones entre la proteína NS3 y otras proteínas celulares. Materiales y métodos: Se expresaron dos proteínas recombinantes del dominio helicasa de NS3 del DENV de serotipo 2, las cuales se emplearon para inmunizar ratas y producir anticuerpos policlonales. Resultados: Los anticuerpos producidos fueron útiles en ensayos de Western blot e inmunofluorescencia y se reportó por primera vez un anticuerpo policlonal anti-NS3 que permitió la inmunoprecipitación de la proteína viral y la detecta con Western blot sin necesidad de inducir sobreexpresión de NS3 o de usar extractos de células marcados metabólicamente con radioisótopos. Conclusión: Las proteínas recombinantes expresadas y los anticuerpos producidos constituyen herramientas valiosas para estudiar procesos infecciosos del DENV que involucren a la proteína NS3 y evaluar pruebas dirigidas a interferir las funciones de esta proteína.


Abstract Introduction: Dengue is a disease caused by one of four serotypes of the dengue virus (DENV) and is endemic in approximately 130 countries. The incidence of dengue has increased dramatically in recent decades, as well as the frequency and magnitude of outbreaks. Despite all efforts, there are no prophylactic or therapeutic treatments for the disease. Accordingly, research on the processes governing the DENV infection cycle is essential to develop vaccines or antiviral therapies. One of the most attractive DENV molecules to investigate is nonstructural protein 3 (NS3), which is essential for viral replication and a major immune target for infection. Objective: To produce antibodies to support future studies on NS3 and its cellular interactions with other proteins. Materials and methods: Two recombinant proteins of the helicase domain of DENV NS3 serotype 2 were expressed, and used to immunize mice and produce polyclonal antibodies. Results: The antibodies produced were useful in Western blot and immunofluorescence tests. We report an NS3 antibody that immunoprecipitates the viral protein and detects it in Western blot with no need to over-express it or use cell extracts with metabolic radiolabeling.


الموضوعات
Animals , Humans , Mice , Virus Replication/physiology , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/metabolism , Dengue/virology , Dengue Virus/immunology , Antibodies, Viral/immunology , Virus Replication/genetics , Virus Replication/immunology , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Serine Endopeptidases/chemistry , Blotting, Western , Viral Nonstructural Proteins/chemistry , RNA Helicases/genetics , RNA Helicases/metabolism , RNA Helicases/chemistry , Antibodies, Viral/metabolism , Antibodies, Viral/chemistry
6.
Arch. endocrinol. metab. (Online) ; 59(1): 4-12, 02/2015. tab, graf
مقالة ي الانجليزية | LILACS | ID: lil-746453

الملخص

Type 1 diabetes mellitus (T1DM) is a chronic, progressive autoimmune disease characterized by metabolic decompensation often leading to dehydration and ketoacidosis. Viral agents seem to play an important role in triggering the autoimmune destruction that leads to the development of T1DM. Among several viral strains investigated so far, the enterovirus family has been consistently associated with the onset of T1DM in humans. One of the mediators of viral damage is the double-stranded RNA (dsRNA) generated during replication and transcription of viral RNA and DNA. The Toll-like receptor 3 (TLR3) gene codes for an endoplasmic receptor of the pattern-recognition receptors (PRRs) family that recognizes dsRNA, plays an important role in the innate immune response triggered by viral infection. Binding of dsRNA to the TLR3 triggers the release of proinflammatory cytokines, such as interferons, which exhibit potent antiviral action; thus, protecting uninfected cells and inducing apoptosis of infected ones. Therefore, the TLR3 gene is a good candidate for the development of T1DM. Within this context, the objective of the present review was to address the role of the TLR3 gene in the development of T1DM. Arch Endocrinol Metab. 2015;59(1):4-12.


الموضوعات
Animals , Humans , Diabetes Mellitus, Type 1/genetics , RNA, Double-Stranded/metabolism , /genetics , Cytokines/metabolism , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/virology , Enterovirus/immunology , Enterovirus/physiology , Immunity, Innate/physiology , Inflammation/metabolism , Insulin-Secreting Cells/metabolism , Signal Transduction/physiology , /metabolism , Virus Replication/genetics , Virus Replication/immunology
7.
Actual. SIDA ; 20(77): 67-75, aug 2012. ilus
مقالة ي الأسبانية | LILACS | ID: lil-665127

الملخص

El virus de la hepatitis C (HCV) ha sido caracterizado en profundidad a nivel molecular en la última década. La partícula viral envuelta alberga una nucleocápside, estructura constituida principalmente por una proteína básica que está en estrecha interacción con el genoma viral representado por una molécula de ARN de cadena simple con polaridad positiva. La organización genómica del HCV es similar a la de Pestivirus y Flavivirus. Diferentes receptores celulares se han postulado en su participación para el ingreso del virus a la célula blanco. Su estrategia de multiplicación deja avizorar los blancos de acción de nuevas drogas para controlar la replicación. Si bien comparte con el HIV - desde su naturaleza de ARN virus - entre otras características virológicas la magnífica plasticidad genómica, otras por el contrario revisten claras diferencias. Ambos virus constituyen un enorme desafío en Salud


The hepatitis C virus (HCV) has been deeply characterized at molecular level during the last decade. The enveloped viral particle protects the nucleocapsid that is essentially constituted by a basic protein that interacts with the viral genome, a single strand RNA with positive polarity. The genomic organization of the HCV is similar to the Pestivirus and Flavivirus. Different cellular receptors have been postulated to play a role to the virus entry in the cellular target. The replication strategy exhibit the different plausible target of antiviral action with new drugs in order to control the replication. The HCV shares with the HIV the vast genomic plasticity because both are RNA viruses but other characteristics are different between them. Both viruses are an enormous trial for human health


الموضوعات
Humans , DNA Replication Timing , Genome, Viral/immunology , HIV , Hepacivirus/genetics , RNA , Virus Replication/immunology , Base Sequence/genetics
8.
J. bras. med ; 98(4): 19-21, ago.-set. 2010. ilus, tab
مقالة ي البرتغالية | LILACS | ID: lil-566750

الملخص

O acesso à terapia antirretroviral (TARV) tem garantido uma melhoria significativa na qualidade de vida dos indivíduos HIV--positivos, sobretudo em países onde a distribuição destes medicamentos é gratuita, como no Brasil. Entretanto, um dos principais fatores associados à falha terapêutica é o surgimento de resistência às drogas e a transmissão de vírus resistentes. O presente artigo apresenta os mecanismos de atuação das drogas antirretrovirais (ARVs) em uso, a epidemiologia da resistência do HIV-I, suas consequências, bem como novas perspectivas de tratamento.


Access to antiretroviral therapy has granted a significant improvement in quality of life for HIV-I positive individuals, especially in countries where treatment is free-of-charge, such as Brazil. However, one of the leading factors associated with treatment failure is the development and transmission of resistant viruses. This present article presents the mechanisms of action of antiretroviral drugs (ARVs) in use, the epidemiology and consequences of HIV-I resistance, and new treatment perspectlves.


الموضوعات
HIV-1 , Acquired Immunodeficiency Syndrome/therapy , Anti-HIV Agents/pharmacokinetics , Anti-HIV Agents/therapeutic use , Viral Load/immunology , Drug Resistance, Viral , HIV Protease Inhibitors , Prevalence , Virus Replication/immunology , Combined Modality Therapy/trends
9.
Mem. Inst. Oswaldo Cruz ; 103(2): 119-129, Mar. 2008. ilus, graf
مقالة ي الانجليزية | LILACS | ID: lil-480638

الملخص

The only long-term and cost-effective solution to the human immunodeficiency virus (HIV) epidemic in the developing world is a vaccine that prevents individuals from becoming infected or, once infected, from passing the virus on to others. There is currently little hope for an AIDS vaccine. Conventional attempts to induce protective antibody and CD8+ lymphocyte responses against HIV and simian immunodeficiency virus (SIV) have failed. The enormous diversity of the virus has only recently been appreciated by vaccinologists, and our assays to determine CD8+ lymphocyte antiviral efficacy are inadequate. The central hypothesis of a CTL-based vaccine is that particularly effective CD8+ lymphocytes directed against at least five epitopes that are derived from regions under functional and structural constraints will control replication of pathogenic SIV. This would be somewhat analogous to control of virus replication by triple drug therapy or neutralizing antibodies.


الموضوعات
Animals , Humans , AIDS Vaccines/immunology , /immunology , Epitopes, T-Lymphocyte/immunology , Simian Immunodeficiency Virus/immunology , DNA, Viral/drug effects , DNA, Viral/immunology , Drug Design , HIV Infections/immunology , HIV Infections/prevention & control , Immune Tolerance , Macaca mulatta , Simian Immunodeficiency Virus/drug effects , Time Factors , Viral Load , Virus Replication/drug effects , Virus Replication/immunology
10.
Acta biol. colomb ; 11(2): 3-20, jul. 2006. ilus
مقالة ي الأسبانية | LILACS | ID: lil-468995

الملخص

El herpesvirus equino (EHV) es uno de los patógenos virales de mayor importancia en la industria equina mundial, debido a las grandes pérdidas económicas que acarrea. La enfermedad comúnmente asociada con el EHV se denomina rinoneumonitis equina y se caracteriza por ser una infección primaria del tracto respiratorio superior, que progresa a través de la mucosa; puede causar aborto en los últimos meses de gestación, muerte perinatal de potros, mortinatos y mieloencefalitis. La infección productiva es seguida por un estado de latencia viral, etapa en la cual el animal no presenta ningún signo clínico de enfermedad y no hay replicación viral. Bajo una situación de estrés, el virus puede reactivarse y caballos infectados infectar a otros caballos sanos. En esta revisión se presenta de manera sintetizada, los principales hallazgos relacionados con la replicación viral y patogénesis molecular del EHV, relacionando además las proteínas implicadas en la regulación de la replicación del genoma, todas las glicoproteínas estructurales que han sido estudiadas hasta el momento y que son el eje central de investigación de distintos grupos en el mundo. Se discute además, la verdadera importancia de la dispersión directa célulacélula del virus, la formación de placas, el crecimiento in vitro y en algunos casos, la asociación con la patogénesis, bien sea en un modelo animal o en el hospedero natural.


الموضوعات
Genome, Viral , Virus Replication/physiology , Virus Replication/genetics , Virus Replication/immunology
11.
مقالة ي الانجليزية | IMSEAR | ID: sea-125251

الملخص

The major causes of chronic liver disease (CLD) are infection with Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) either alone or together. The clinical course of the disease varies in cases ofcoinfection with HCV and HBV as compared to single infection. The present study was carried out to determine the occurrence of coinfection of HCV with HBV in CLD patients and to look for the presence of suppressive effect of the two viruses on each other. The severity of liver disease was also assessed and correlated with biochemical profiles. Sera from 150 patients of CLD were tested serologically for the presence of HBsAg, IgG anti HBc and anti-HCV antibodies. HBV DNA and HCV RNA were also detected by amplifying surface region and 5' noncoding-core region respectively by polymerase chain reaction. Forty-seven (31.3%) cases showed the presence of HBsAg or anti IgG-HBc or HBV DNA either alone or together (Group A). Thirty-nine (26%) cases were found to be positive for HCV by detecting either anti-HCV antibodies or HCV RNA (Group B). Coinfection ofHCV with HBV (Group C) could be detected in twenty-four (16%) cases, of these twenty-one cases (87.5%) were positive both for HCV RNA and IgG anti-HBc without the presence of HBV DNA whereas in none of the cases could HBV DNA be detected in the absence of HCV RNA. Forty (26.6%) cases had neither HCV or HBV related CLD. Amongst, the biochemical parameters, the liver function test profiles were altered and found to be statistically significantly in HCV positive cases (Group B) when compared to the negative ones while in case of HBV (Group A) and coinfected (Group C) cases none of the parameters was statistically significant when compared with non-HBV and non-coinfected cases respectively. Thus, coinfection of HCV with HBV is seen in a substantial number of CLD cases. It is also revealed from the present study that HCV infection has a suppressive effect on the replication of HBV as seen by the loss of replicative markers like HBV DNA.


الموضوعات
Comorbidity , DNA, Viral/analysis , Hepacivirus/physiology , Hepatitis B virus/physiology , Hepatitis B, Chronic/epidemiology , Hepatitis C, Chronic/epidemiology , Humans , India/epidemiology , Liver Cirrhosis/epidemiology , Prevalence , Severity of Illness Index , Virus Replication/immunology
12.
An. méd. Asoc. Méd. Hosp. ABC ; 43(4): 151-63, oct.-dic. 1998. ilus, tab
مقالة ي الأسبانية | LILACS | ID: lil-240951

الملخص

Desde el reconocimiento del síndrome de inmunodeficiencia adquirida en 1981 y conociendo las repercusiones médicas, sociales y económicas, diferentes esfuerzos han sido dirigidos hacia la prevención de la enfermedad. Otro aspecto importante ha sido el entendimiento del ciclo replicativo del virus, lo cual ha permitido intervenciones farmacológicas en diferentes pasos críticos de la replicación viral. El tratamiento de la infección por virus de la inmunodeficiencia humana (VIH) puede dividirse en tres grandes etapas: La monoterapia con zidovudina en 1986; el tratamiento combinado con inhibidores de transcriptasa reversa análogos de nucleósidos desde 1995 y la terapia triple con inhibidores de transcriptasa reversa análogos de nucleósidos e inhibidores de proteasas a partir de 1996. Aún existe controversia en qué tan temprano o qué tan agresivo deberá ser el inicio de tratamiento. En los pacientes en quienes se decide iniciar tratamiento antirretroviral, la tendencia actual es utilizar aquella combinación de fármacos que permitan el mayor grado de supresión en la actividad replicativa del virus, pero con el menor riesgo de condicionar resistencia. A este tipo de recurso terapéutico es lo que se ha denominado "terapia antirretroviral activa altamente efectiva". La carga viral sigue siendo el mejor marcador de progresión de la enfermedad y si se combina con determinación de linfocitos CD4+, se puede realizar una mejor evaluación y seguimiento de los pacientes bajo terapia antirretroviral, permitiéndonos definir " falla al tratamiento" y ayudando a definir aquellos pacientes que ameritan cambios en el esquema antirretroviral inicial. Nosotros analizamos 29 pacientes con infección por el virus de inmunodeficiencia humana en diferentes estadios clínicos de la enfermedad en quienes se dio terapia antirretroviral activa "altamente efectiva" y analizamos el comportamiento de la carga viral y en cuenta de linfocitos CD4+


الموضوعات
Humans , Male , Female , Adult , Antiviral Agents/immunology , CD4 Lymphocyte Count , Drug Resistance/immunology , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , HIV-1/immunology , HIV-1/pathogenicity , Virus Replication , Virus Replication/immunology , Acquired Immunodeficiency Syndrome/epidemiology , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/virology
13.
An. méd. Asoc. Méd. Hosp. ABC ; 43(4): 164-9, oct.-dic. 1998. tab
مقالة ي الأسبانية | LILACS | ID: lil-240952

الملخص

El síndrome de inmunodeficiencia adquirida fue descrito desde 1981. El primer medicamento con efecto antirretroviral aprobado fue la zidovudina en 1987. Desde entonces han surgido una gran cantidad de nuevos medicamentos y combinaciones de éstos para intentar la curación o, al menos, el control de la progresión de esta terrible infección. Existen nuevas formas de monitorizar la evolución y respuesta al tratamiento que han permitido establecer esquemas de tratamiento específicos para cada caso. La meta en el tratamiento de la infección por virus de la inmunodeficiencia humana es lograr la supresión de la replicación viral. En este artículo se revisan las nuevas opciones de tratamiento y seguimiento del paciente con infección por el virus de la inmunodeficiencia humana


الموضوعات
Humans , Antiviral Agents/adverse effects , Antiviral Agents/immunology , Antiviral Agents/pharmacokinetics , CD4 Lymphocyte Count/drug effects , HIV-1/drug effects , HIV-1/immunology , HIV-1/pathogenicity , Virus Replication , Virus Replication/genetics , Virus Replication/immunology , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/virology
14.
Mem. Inst. Oswaldo Cruz ; 93(6): 815-8, Nov.-Dec. 1998. ilus, tab
مقالة ي الانجليزية | LILACS | ID: lil-223887

الملخص

Prostaglandins (Pgs) have been shown to inhibit the replication of several DNA and RNA viruses. Here we report the effect of prostaglandin (PgA1) on the multiplication of a positive strand RNA virus, Classical Swine Fever Virus (CSFV) in PK15 cells. PgA1 was found to inhibit the multiplication of CSFV. At a concentration of 5 µg/ml, which was nontoxic to the cell, PgA1 inhibits virus production in 99 per cent. In PgA1 treated cells the size and number of characteristic Classical Swine Fever focus decreased in amount.


الموضوعات
Animals , Prostaglandins A , Virus Replication/immunology
15.
Rev. argent. infectol ; 11(4): 15-24, 1998.
مقالة ي الأسبانية | LILACS | ID: lil-240643

الملخص

Algunos descubrimientos recientes han permitido un mejor conocimiento de la fisiopatología de la enfermedad debida al HIV, lo que ha producido un cambio de las teorías hasta ahora aceptadas acerca de la replicación viral. De acuerdo con un modelo matemático recientemente desarrollado, la replicación viral alcanza proporciones astronómicas, lo que acompañado a numerosos errores que ocurren durante la transcripción del ARN permite la aparición de nuevas cuasi-especies. Las cepas mutantes son responsables en parte del fracaso de la monoterapia, hecho que es superado por la administración de tratamiento combinado que disminuye la replicación viral. Estos nuevos agentes terapéuticos han logrado aumentar el número de linfocitos TCD4(+) y reducir los niveles de la carga viral. Recientes publicaciones muestran que un pequeño grupo de pacientes presentaron infecciones oportunistas con un recuento de CD4 alto a pesar de estar recibiendo Terapéutica Antiviral Altamente Efectiva (HAART sus siglas en inglés). Por otro lado, algunos enfermos resolvieron sus patologías oportunistas a pesar de no recibir tratamiento específico contra las mismas, excepto HAART. Estos conceptos, y también otros referidos a la dinámica viral y la restauración inmune, son analizados en la presente revisión


الموضوعات
Humans , AIDS-Related Opportunistic Infections/immunology , CD4-Positive T-Lymphocytes/virology , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , Mutagenesis , Mutation , Virus Replication/immunology , Viral Load , Virion/immunology
16.
Rev. Inst. Med. Trop. Säo Paulo ; Rev. Inst. Med. Trop. Säo Paulo;38(4): 253-8, jul.-ago. 1996. ilus, tab
مقالة ي الانجليزية | LILACS | ID: lil-182826

الملخص

A fim de avaliar as consequencias da infeccao por HIV no curso da infeccao por HBV, ou na imunidade anteriormente adquirida, estudamos um grupo de 66 doentes Caucasoides HIV1+ sintomaticos e outro de 38 individuos seropositivos para HIV2 e provenientes da Africa, quanto a marcadores serologicos de infeccao por HBV e quanto a presenca de DNA viral circulante, tomada como sinal de replicacao do virus da hepatite. Os grupos HIV+ foram comparados com controles seronegativos adequados tendo-se verificado que 7,6 por cento dos doentes HIV1+ eram tambem HBV-DNA+ (versus 3,2 por cento nos seronegativos) bem como 2,6 por cento dos HIV2+ (versus 2,9 por cento nos controles seronegativos), nao sendo as diferencas estatisticamente significativas em qualquer um dos casos e nao tendo sido encontrada correlacao entre infeccao por HIV e replicacao ativa de HBV...


الموضوعات
Humans , Male , Female , Adult , Hepatitis B/immunology , Hepatitis, Chronic/immunology , Acquired Immunodeficiency Syndrome/immunology , Virus Replication/immunology , Hepatitis B virus/isolation & purification
اختيار الاستشهادات
تفاصيل البحث